$20.38
0.22% today
NYSE, Apr 01, 06:44 pm CET
ISIN
IT0005452658
Symbol
STVN
Industry

Stevanato Group Spa Stock price

$20.42
+1.78 9.55% 1M
+0.42 2.10% 6M
-1.37 6.29% YTD
-10.91 34.82% 1Y
+0.30 1.49% 3Y
+0.75 3.81% 5Y
+0.75 3.81% 10Y
NYSE, Closing price Mon, Mar 31 2025
+0.13 0.64%
ISIN
IT0005452658
Symbol
STVN
Industry

Key metrics

Market capitalization $5.57b
Enterprise Value $5.92b
P/E (TTM) P/E ratio 43.64
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.96
P/S ratio (TTM) P/S ratio 4.67
P/B ratio (TTM) P/B ratio 3.83
Dividend yield 0.28%
Last dividend (FY23) $0.06
Revenue growth (TTM) Revenue growth 1.72%
Revenue (TTM) Revenue $1.19b
EBIT (operating result TTM) EBIT $164.26m
Free Cash Flow (TTM) Free Cash Flow $-156.62m
Cash position $101.76m
EPS (TTM) EPS $0.47
P/E forward 36.37
P/S forward 4.36
EV/Sales forward 4.63
Short interest 6.86%
Show more

Is Stevanato Group Spa a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Stevanato Group Spa Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Stevanato Group Spa forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Stevanato Group Spa forecast:

Buy
73%
Hold
27%

Financial data from Stevanato Group Spa

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,193 1,193
2% 2%
100%
- Direct Costs 881 881
7% 7%
74%
313 313
11% 11%
26%
- Selling and Administrative Expenses 34 34
18% 18%
3%
- Research and Development Expense 31 31
8% 8%
3%
249 249
14% 14%
21%
- Depreciation and Amortization 84 84
1% 1%
7%
EBIT (Operating Income) EBIT 164 164
20% 20%
14%
Net Profit 127 127
19% 19%
11%

In millions USD.

Don't miss a Thing! We will send you all news about Stevanato Group Spa directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Stevanato Group Spa Stock News

Neutral
Business Wire
21 days ago
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Healthcare Forum taking place from Tuesday, March 18 to Wednesday, March 19, 2025. The Company...
Negative
Seeking Alpha
23 days ago
Stevanato's 2024 revenue reached €1.1 billion, surpassing analyst expectations. This growth was driven by Biopharmaceutical and Diagnostic Solutions, despite a challenging year with inventory issues. Investments in expanding facilities in Latina and Fishers aim to meet rising product demand, and a significant sales increase is expected. Supportive CAPEX investment in different GEO provides down...
Neutral
Seeking Alpha
26 days ago
Stevanato Group S.p.A. (NYSE:STVN ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Lisa Miles - SVP, IR Franco Stevanato - Chairman and CEO Marco Dal Lago - CFO Conference Call Participants Michael Ryskin - Bank of America Matt Larew - William Blair Patrick Donnelly - Citi David Windley - Jefferies Pete Lukas - CJS Securities Anna Snopkowski - KeyBanc Tejas Savan...
More Stevanato Group Spa News

Company Profile

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates in Biopharmaceutical and Diagnostic Solutions and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.

Head office Italy
CEO Franco Stevanato
Founded 1996
Website www.stevanatogroup.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today